TY - JOUR T1 - ▼Naloxegol for opioid-induced constipation JF - Drug and Therapeutics Bulletin JO - Drug Ther Bull SP - 138 LP - 140 DO - 10.1136/dtb.2015.12.0369 VL - 53 IS - 12 A2 - , Y1 - 2015/12/01 UR - http://dtb.bmj.com/content/53/12/138.abstract N2 - ▼Naloxegol (Moventig—AstraZeneca) is a peripherally acting mu-opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative treatment.1 It was launched in the United Kingdom in October 2015. Here, we review the evidence for naloxegol and consider its place in the management of opioid-induced constipation. ER -